BAJAJ BROKING

open-demat-imgOpen Demat
Login-imgLoginopens in a new tab
be-a-partner-imgBe a Partner
samadhan-imgSamadhanopens in a new tab
open-demat-imgOpen Demat
InstallInstall App
Download AppInstall App
Notification
Shri Ahimsa Naturals IPO is Open!
Apply for the Shri Ahimsa Naturals IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
Trade Nowopens in a new tab
framedot
img
dr. reddy s laboratories stock

Dr. Reddy S Laboratories Share Price

₹ 1162.20 -2.40 (-0.20%)
Mar 27 2025 03:30 PM Pharmaceuticals NSE: DRREDDY

Dr. Reddy S Laboratories Share Price Update

As of the latest trading session, Dr. Reddy S Laboratories share price is currently at 1162.2, which is down by -2.40 from its previous closing. Today, the stock has fluctuated between 1144.00 and 1172.40. Over the past year, Dr. Reddy S Laboratories has achieved a return of -5.08 %. In the last month alone, the return has been 3.46 %. Read More...

Dr. Reddy S Laboratories Performance

Day Range

Low1144.00 High1172.40
1162.20

52 Week Range

Low 1092.45 High 1421.49
1162.20

Dr. Reddy S Laboratories Share Price

881

500124

DRREDDY

img img img img
Compare to down-arrow
View down-arrow
Display down-arrow
Studies down-arrow

Open Price

1160.00

Prev. Close

1164.60

Volume (Shares)

44,60,409

Total traded value

51838.87 (₹ Lakhs)

Upper Circuit

1281.05

Lower Circuit

1048.15

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Dr. Reddy S Laboratories Fundamentals


(Standalone)

Market Cap (Cr) 19387.62
PE Ratio (TTM) 18.74
Book Value / Share 322.46
Beta 0.49
ROE 19.42%
EPS (TTM) 62.12
Dividend Yield 0.69%
Net Profit Qtr (Cr) 849.40

Dr. Reddy S Laboratories Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

(Values in Cr)8000.08000.06000.06000.04000.04000.02000.02000.00.00.0
  • Dec 2024
  • Sep 2024
  • Jun 2024
  • Mar 2024
  • Dec 2023
Particulars Dec 2024 (Values in Cr)
Revenue 4997.80
Operating Expense 4131.00
Net Profit 849.40
Net Profit Margin (%) 16.99
Earnings Per Share (EPS) 10.20
EBITDA 1427.80
Effective Tax Rate (%) 24.12
Particulars Dec 2024 (Values in Cr)
Revenue 6678.80
Operating Expense 4263.09
Net Profit 1882.10
Net Profit Margin (%) 28.18
Earnings Per Share (EPS) 113.00
EBITDA 2929.20
Effective Tax Rate (%) 28.72
Particulars Dec 2024 (Values in Cr)
Revenue 5823.90
Operating Expense 4145.10
Net Profit 1417.20
Net Profit Margin (%) 24.33
Earnings Per Share (EPS) 85.10
EBITDA 2170.80
Effective Tax Rate (%) 25.95
Particulars Dec 2024 (Values in Cr)
Revenue 5081.80
Operating Expense 3978.30
Net Profit 1034.80
Net Profit Margin (%) 20.36
Earnings Per Share (EPS) 62.14
EBITDA 1591.30
Effective Tax Rate (%) 22.72
Particulars Dec 2024 (Values in Cr)
Revenue 4083.10
Operating Expense 3698.70
Net Profit 475.20
Net Profit Margin (%) 11.63
Earnings Per Share (EPS) 28.55
EBITDA 883.90
Effective Tax Rate (%) 24.79
Particulars Dec 2024 (Values in Cr)
Revenue 19404.10
Operating Expense 14554.80
Net Profit 4342.00
Net Profit Margin (%) 22.37
Earnings Per Share (EPS) 260.95
EBITDA 6788.70
Effective Tax Rate (%) 25.02
Particulars Dec 2024 (Values in Cr)
Revenue 16899.10
Operating Expense 13687.80
Net Profit 2612.80
Net Profit Margin (%) 15.46
Earnings Per Share (EPS) 157.37
EBITDA 4806.10
Effective Tax Rate (%) 32.41
Particulars Dec 2024 (Values in Cr)
Revenue 14315.30
Operating Expense 12663.40
Net Profit 1623.20
Net Profit Margin (%) 11.33
Earnings Per Share (EPS) 97.85
EBITDA 3076.10
Effective Tax Rate (%) 27.00
Particulars Dec 2024 (Values in Cr)
Revenue 13281.40
Operating Expense 11094.00
Net Profit 2186.40
Net Profit Margin (%) 16.46
Earnings Per Share (EPS) 131.84
EBITDA 3937.89
Effective Tax Rate (%) 28.46
Particulars Dec 2024 (Values in Cr)
Revenue 11803.00
Operating Expense 9817.80
Net Profit 2937.70
Net Profit Margin (%) 24.88
Earnings Per Share (EPS) 177.23
EBITDA 3612.80
Effective Tax Rate (%) -5.83
Particulars Dec 2024 (Values in Cr)
Book Value / Share 1699.87
ROE % 21.64
ROCE % 26.59
Total Debt to Total Equity 0.06
EBITDA Margin 31.57
Particulars Dec 2024 (Values in Cr)
Book Value / Share 1405.34
ROE % 21.21
ROCE % 25.99
Total Debt to Total Equity 0.11
EBITDA Margin 30.16
Particulars Dec 2024 (Values in Cr)
Book Value / Share 1164.21
ROE % 11.84
ROCE % 14.46
Total Debt to Total Equity 0.17
EBITDA Margin 20.06
Particulars Dec 2024 (Values in Cr)
Book Value / Share 1072.02
ROE % 11.74
ROCE % 15.29
Total Debt to Total Equity 0.16
EBITDA Margin 22.10
Particulars Dec 2024 (Values in Cr)
Book Value / Share 944.61
ROE % 13.68
ROCE % 10.95
Total Debt to Total Equity 0.20
EBITDA Margin 17.97
Particulars Dec 2024 (Values in Cr)
Book Value / Share 1459.23
ROE % 19.42
ROCE % 25.40
Total Debt to Total Equity 0.02
EBITDA Margin 34.84
Particulars Dec 2024 (Values in Cr)
Book Value / Share 1236.56
ROE % 13.46
ROCE % 18.82
Total Debt to Total Equity 0.06
EBITDA Margin 28.33
Particulars Dec 2024 (Values in Cr)
Book Value / Share 1111.56
ROE % 9.19
ROCE % 11.63
Total Debt to Total Equity 0.10
EBITDA Margin 21.35
Particulars Dec 2024 (Values in Cr)
Book Value / Share 1032.48
ROE % 11.50
ROCE % 15.04
Total Debt to Total Equity 0.08
EBITDA Margin 25.97
Particulars Dec 2024 (Values in Cr)
Book Value / Share 920.13
ROE % 21.08
ROCE % 18.48
Total Debt to Total Equity 0.09
EBITDA Margin 30.49
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 1727.70
Total Assets 38863.80
Total Liabilities 38863.80
Total Equity 28254.80
Share Outstanding 166818266
Price to Book Ratio 4.22
Return on Assets (%) 14.35
Return on Capital (%) 18.65
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 1730.20
Total Assets 32285.10
Total Liabilities 32285.10
Total Equity 23286.10
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 13.96
Return on Capital (%) 18.47
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 2419.20
Total Assets 29746.90
Total Liabilities 29746.90
Total Equity 19212.40
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 7.33
Return on Capital (%) 9.79
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 2078.80
Total Assets 26616.80
Total Liabilities 26616.80
Total Equity 17641.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 7.33
Return on Capital (%) 9.6
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 205.30
Total Assets 23225.30
Total Liabilities 23225.30
Total Equity 15598.80
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 8.72
Return on Capital (%) 11.66
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 1216.90
Total Assets 30359.30
Total Liabilities 30359.30
Total Equity 24240.80
Share Outstanding 166818466
Price to Book Ratio 4.22
Return on Assets (%) 14.30
Return on Capital (%) 17.4
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 645.80
Total Assets 25374.80
Total Liabilities 25374.80
Total Equity 20474.20
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 10.29
Return on Capital (%) 12.76
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 2030.50
Total Assets 24495.60
Total Liabilities 24495.60
Total Equity 18336.20
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 6.62
Return on Capital (%) 7.92
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 1646.50
Total Assets 21629.60
Total Liabilities 21629.60
Total Equity 16983.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 10.10
Return on Capital (%) 12.04
Particulars Dec 2024 (Values in Cr)
Cash & Short Term Investments 39.20
Total Assets 19475.80
Total Liabilities 19475.80
Total Equity 15191.90
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 15.08
Return on Capital (%) 18.07
Particulars Dec 2024 (Values in Cr)
Net Income 7201.00
Cash from Operations 6548.00
Cash from Investing -4028.30
Cash from Financing -376.30
Net change in Cash 138.70
Free Cash Flow 8188.30
Particulars Dec 2024 (Values in Cr)
Net Income 6048.50
Cash from Operations 6958.90
Cash from Investing -4137.30
Cash from Financing -2686.10
Net change in Cash -935.90
Free Cash Flow 8091.20
Particulars Dec 2024 (Values in Cr)
Net Income 3061.40
Cash from Operations 3554.50
Cash from Investing -2638.70
Cash from Financing -242.20
Net change in Cash -70.10
Free Cash Flow 5020.50
Particulars Dec 2024 (Values in Cr)
Net Income 2883.50
Cash from Operations 4141.90
Cash from Investing -2266.00
Cash from Financing -29.80
Net change in Cash 1274.50
Free Cash Flow 5116.00
Particulars Dec 2024 (Values in Cr)
Net Income 1885.70
Cash from Operations 3694.60
Cash from Investing -492.30
Cash from Financing -2515.90
Net change in Cash -24.10
Free Cash Flow 4179.20
Particulars Dec 2024 (Values in Cr)
Net Income 5791.30
Cash from Operations 4769.20
Cash from Investing -3430.30
Cash from Financing 68.10
Net change in Cash 87.50
Free Cash Flow 6130.29
Particulars Dec 2024 (Values in Cr)
Net Income 3866.00
Cash from Operations 5835.60
Cash from Investing -3447.60
Cash from Financing -2696.90
Net change in Cash -1091.60
Free Cash Flow 6835.80
Particulars Dec 2024 (Values in Cr)
Net Income 2223.80
Cash from Operations 1827.50
Cash from Investing -2038.00
Cash from Financing 505.50
Net change in Cash -193.80
Free Cash Flow 3138.80
Particulars Dec 2024 (Values in Cr)
Net Income 3056.20
Cash from Operations 3962.20
Cash from Investing -1458.00
Cash from Financing -794.30
Net change in Cash 1261.90
Free Cash Flow 4819.70
Particulars Dec 2024 (Values in Cr)
Net Income 2775.80
Cash from Operations 2316.10
Cash from Investing -1689.20
Cash from Financing -224.10
Net change in Cash -74.10
Free Cash Flow 2742.29

Dr. Reddy S Laboratories Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
1162.20 redarrow -0.20
red-green-graph indicator
Bullish Moving Averages 3
Bearish Moving Averages 13
  • 5 Days 1177.30
  • 26 Days 1168.20
  • 10 Days 1169.20
  • 50 Days 1191.70
  • 12 Days 1166.70
  • 100 Days 1226.40
  • 20 Days 1164.60
  • 200 Days 1240.50

Dr. Reddy S Laboratories Future

Future: Price

27 Mar
1155.4
24 Apr
1146
29 May
1144.45
25 May
03507001K1.4K

Discount/Premium

27 Mar
-6.8
24 Apr
-16.2
29 May
-17.75
25 May
06111722

Active Calls (Expiry: 27 Mar 2025)

Strike

1,150
2371
1,160
1253
1,170
1092
25 May
07251.4K2.1K2.9K

Active Puts (Expiry: 27 Mar 2025)

Strike

1,150
1712
1,140
1044
1,160
466
25 Jul
05251K1.5K2.1K

Dr. Reddy S Laboratories Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Stock Holding

View Live Stock Screeners

arrow-right

Holding

Public
10.37
Promoter Holdings
26.64
FII
40.07
DII
22.9
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
J P Morgan Chase Bank Na Public Shareholding 1.10414975E8 13.23
G V Prasad Shareholding of Promoter and Promoter Group 9.609592E7 11.52
Satish Reddy Kallam Shareholding of Promoter and Promoter Group 8.013563E7 9.6
Life Insurance Corporation Of India P & Gs Fund Public Shareholding 5.4208796E7 6.5
Kallam Satish Reddy Huf Shareholding of Promoter and Promoter Group 2.7618385E7 3.31
Nps Trust-a/c Sbi Pension Fund Scheme Tax Saver-tier 2 Public Shareholding 2.13002E7 2.55
Icici Prudential Value Discovery Fund Public Shareholding 1.9824052E7 2.38
First Sentier Investors Icvc - Stewart Investors Asia Pacific Leaders Sustainability Fund Public Shareholding 1.9345625E7 2.32
Nippon Life India Trustee Ltd-a/c-nippon India Nifty 50 Value 20 Index Fund Public Shareholding 1.5236897E7 1.83
Gunupati Venkateswara Prasad Huf Shareholding of Promoter and Promoter Group 1.271709E7 1.52
Sbi Nifty Index Fund Public Shareholding 1.0772198E7 1.29
Samrajyam Reddy Kallam Shareholding of Promoter and Promoter Group 5602495.0 0.67
Anuradha Gunupati Shareholding of Promoter and Promoter Group 46025.0 0.01
Sharathchandra Reddy Gunupati Shareholding of Promoter and Promoter Group 13000.0 0.0
Aps Trust Shareholding of Promoter and Promoter Group 0.0 0.0
Vsd Holdings & Advisory Llp Shareholding of Promoter and Promoter Group 0.0 0.0
K Vishal Reddy Shareholding of Promoter and Promoter Group 0.0 0.0
K Shravya Reddy Shareholding of Promoter and Promoter Group 0.0 0.0
Gunupati Mallika Reddy Shareholding of Promoter and Promoter Group 25695.0 0.0
G Vani Sanjana Reddy Shareholding of Promoter and Promoter Group 25700.0 0.0
Deepti Reddy Kallam Shareholding of Promoter and Promoter Group 25700.0 0.0

Dr. Reddy S Laboratories

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
11 Jul, 202340Final12 Jul, 2023Equity shares
11 Jul, 202230Final13 Jul, 2022Equity shares
09 Jul, 202125Final13 Jul, 2021Equity shares
13 Jul, 202025Final15 Jul, 2020Equity shares
15 Jul, 201920Final17 Jul, 2019Equity shares
16 Jul, 201820Final18 Jul, 2018Equity shares
17 Jul, 201720Final19 Jul, 2017Equity shares
18 Jul, 201620Final20 Jul, 2016Equity shares
10 Jul, 201520Final14 Jul, 2015Equity shares
11 Jul, 201418Final15 Jul, 2014Equity shares
12 Jul, 201315Final16 Jul, 2013Equity shares
28 Jun, 201213.75Final03 Jul, 2012Equity shares
30 Jun, 201111.25Final05 Jul, 2011Equity shares
02 Jul, 201011.25Final06 Jul, 2010Equity shares
03 Jul, 20096.25Final07 Jul, 2009Equity shares
04 Jul, 20083.75Final08 Jul, 2008Equity shares
06 Jul, 20073.75Final10 Jul, 2007Equity shares
07 Jul, 20060Final11 Jul, 2006Equity shares
07 Jul, 20050Final11 Jul, 2005Equity shares

Dr Reddy's Laboratories Limited Overview

Dr. Reddy's Laboratories Ltd, an eminent pharmaceutical company based in India, offers an extensive portfolio across Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations. Dominating its revenue, the Global Generics Segment, constituting about 83% in FY22, includes over 400 generic drugs with significant contributions from nervous system, gastrointestinal, and anti-infective drugs. The Pharmaceutical Services & Active Ingredients (PSAI) segment, accounting for 14% of revenues, underscores its position as one of the world's largest API manufacturers, benefiting its generics business with cost competitiveness. Meanwhile, its proprietary products focus on differentiated formulations, with subsidiary Aurgene Discovery advancing novel therapeutics for cancer and inflammation. Geographically, the USA leads its revenue share at 37%, followed by India and Russia. The company boasts 23 manufacturing facilities worldwide and maintains a strategic focus on niche products, injectables, and biosimilars to enhance profitability. FY21 saw partnerships for COVID-19 treatments, including the launch of the Sputnik-V vaccine in India. Recent divestments and acquisitions, such as the portfolio from Eton Pharmaceuticals, reflect its commitment to streamlining operations and expanding its product offerings, supporting its mission to provide affordable medications globally.

Dr Reddy Share Result Highlights

Metric

Value

Share Price (NSE)

₹1272.05 (as of 12 Nov 2024)

Market Cap

₹21,220.12 Cr (Q3 2024)

Day Range

₹1269.20 - ₹1288.40 (12 Nov 2024)

52-Week Range

₹1074.00 - ₹1421.49 (2023-2024)

Volume (Shares)

2,86,546 (12 Nov 2024)

PE Ratio (TTM)

22.35 (Q3 2024)

Earnings Per Share (EPS)

₹113.00 (Q3 2024)

Dividend Yield

0.62% (Q3 2024)

Net Profit Margin

28.18% (Q3 2024)

Effective Tax Rate

28.72% (Q3 2024)

Key Highlights

  • Dr Reddy share price currently stands at ₹1272.05 as of 12 Nov 2024, reflecting recent trading data.

  • Market Cap for Dr Reddy's reached ₹21,220.12 Cr in Q3 2024, emphasising its market strength.

  • Trading Volume shows high activity with 2,86,546 shares traded on 12 Nov 2024.

  • EPS for Dr Reddy's is ₹113.00 in Q3 2024, indicating solid earnings.

  • Dividend Yield for Dr Reddy shares recorded at 0.62% in Q3 2024, offering attractive shareholder returns.

Dr Reddy Share Annual Reports

Metric

Value

Annual Revenue

₹6678.80 Cr (Sep 2024)

Net Profit

₹1882.10 Cr (Sep 2024)

Operating Expense

₹4263.09 Cr (Sep 2024)

EBITDA

₹2929.20 Cr (Sep 2024)

Net Profit Margin

28.18% (Sep 2024)

Return on Equity (ROE)

19.42% (Q3 2024)

Book Value per Share

₹322.48 (Q3 2024)

Key Highlights

  • Dr Reddy share price is influenced by strong annual revenue, reaching ₹6678.80 Cr as of Sep 2024.

  • Net Profit stands at ₹1882.10 Cr (Sep 2024), underscoring profitability.

  • Operating Expense recorded at ₹4263.09 Cr for Sep 2024, highlighting operational control.

  • EBITDA of ₹2929.20 Cr (Sep 2024) reflects robust earnings before tax.

  • Indicators from this performance may impact Dr Reddy future share price, as market outlook is often shaped by financial stability.

Dr Reddy Share Dividend

Dividend Type

Dividend Amount

Ex-Date

Record Date

Final

₹40 per share

11 Jul 2023

12 Jul 2023

Final

₹30 per share

11 Jul 2022

13 Jul 2022

Final

₹25 per share

09 Jul 2021

13 Jul 2021

Final

₹25 per share

13 Jul 2020

15 Jul 2020

Final

₹20 per share

15 Jul 2019

17 Jul 2019

Final

₹20 per share

16 Jul 2018

18 Jul 2018

Key Highlights

  • Dr Reddy share price reflects consistent returns with regular dividends, enhancing investor confidence.

  • The most recent dividend was ₹40 per share with an ex-date of 11 Jul 2023.

  • Dr Reddy's long-term dividend history showcases its commitment to rewarding shareholders.

About Dr. Reddy S Laboratories

Dr Reddy's Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include - USA, India, Russia & CIS countries, and Europe.

Dr Reddy's Laboratories was incorporated in the year 1984 in Hyderabad. The company was established by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh. The company made their beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (API) and commenced operations with a single drug in a 60-tonne facility near Hyderabad, India. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Also, they entered international market with exports of Methyldopa.

Read More

Parent Organisation

Dr. Reddy's

Headquarters

Hyderabad

Founded

1984

NSE Symbol

DRREDDY

Exchange

NSE,BSE

  • Board of directors

G V Prasad

Co-Chairman & Managing Directo

K Satish Reddy

Executive Chairman

Shikha Sanjaya Sharma

Independent Director

Leo Puri

Lead Independent Director

K P Krishnan

Independent Director

Pennv Wan

Independent Director

Learn More About Stocks

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

Invest
investment-card-icon

IPOs

Your gateway to future financial opportunities

Invest
investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

Invest
investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

Invest
investment-card-icon

Frequently Asked Questions

What is the Share Price of Dr Reddys Laboratories Ltd?

Answer Field

The share price of Dr Reddys Laboratories Ltd for NSE is ₹ 1162.2 and for BSE is ₹ 1160.1.

What is the Market Cap of Dr Reddys Laboratories Ltd?

Answer Field

The market cap of Dr Reddys Laboratories Ltd for NSE is ₹ 1,93,87.62 Cr. and for BSE is ₹ 1,93,52.59 Cr. as of now.

What is the 52 Week High and Low of Dr Reddys Laboratories Ltd?

Answer Field

The 52 Week High and Low of Dr Reddys Laboratories Ltd for NSE is ₹ 1421.49 and ₹ 1092.45 and for BSE is ₹ 1420.20 and ₹ 1093.00.

How to Buy Dr Reddys Laboratories Ltd share?

Answer Field

You can trade in Dr Reddys Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Dr Reddys Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -5.08%.

What is the Current Share Price of Dr Reddys Laboratories Ltd?

Answer Field

Dr Reddys Laboratories Ltd share price is for NSE ₹ 1162.2 & for BSE ₹ 1160.1 as on Mar 27 2025 03:30 PM.

What is the Market Cap of Dr Reddys Laboratories Ltd Share?

Answer Field

The market cap of Dr Reddys Laboratories Ltd for NSE ₹ 1,93,87.62 & for BSE ₹ 1,93,52.59 as on Mar 27 2025 03:30 PM.

What is the P/E Ratio of Dr Reddys Laboratories Ltd Share?

Answer Field

As on Mar 27 2025 03:30 PM the price-to-earnings (PE) ratio for Dr Reddys Laboratories Ltd share is 18.74.

What is the PB ratio of Dr Reddys Laboratories Ltd Share?

Answer Field

As on Mar 27 2025 03:30 PM, the price-to-book (PB) ratio for Dr Reddys Laboratories Ltd share is 322.46.

How to Buy Dr Reddys Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Dr Reddys Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Dr Reddys Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Popular FAQs

Who is the CEO of Dr Reddy's Laboratories Ltd?

Erez Israeli has held the position of CEO at Dr Reddy's Laboratories Ltd since 1 Aug 2019. He leads the company in advancing pharmaceutical innovations and global market reach, focusing on sustainable growth and maintaining Dr Reddy's competitive position within the industry.

 

When was Dr Reddy's Laboratories Ltd established?

Dr Reddy's Laboratories Ltd was founded in 1984 in Hyderabad, India, by Dr. Anji Reddy. The company began by manufacturing Active Pharmaceutical Ingredients (APIs) and quickly expanded to become one of India’s leading pharmaceutical companies with a significant global presence.

 

What factors influence the Dr Reddy Share Price?

Dr Reddy share price is influenced by multiple factors, including financial performance, revenue growth, and profitability. Sector trends, global market conditions, regulatory changes, and investor sentiment also impact share value, shaping the overall market perception of Dr Reddy's potential for future growth.

 

Is Dr Reddy's Laboratories Ltd debt free?

Dr Reddy's Laboratories Ltd is not entirely debt-free; however, the company maintains a balanced debt-to-equity ratio, ensuring debt levels remain manageable. This strategic financial management allows Dr Reddy's to invest in growth opportunities while maintaining financial stability and supporting long-term shareholder value.

 

What is the CAGR of Dr Reddy Share?

The Compound Annual Growth Rate (CAGR) for Dr Reddy share is 6% over 10 years, 19% over 5 years, 10% over 3 years, and 19% over the last year. These figures reflect the company’s growth trajectory and its consistent performance in the pharmaceutical sector.

 

How has the Dr Reddy Share Price performed over the past year?

Over the past year, Dr Reddy share price has demonstrated a positive performance, showing a 19% growth in CAGR. This growth highlights investor confidence and reflects the company’s strong market position, profitability, and financial resilience within the highly competitive pharmaceutical industry.

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download
9 lakh+ Users
icon-with-text
4.3+ App Rating
icon-with-text
4 Languages
icon-with-text
₹4300+ Cr MTF Book
icon-with-text
Open Demat Account

TRENDING CALCULATORS AND STOCKS ON BAJAJ BROKING

Popular Stock

top-popular-on-bfsl

POPULAR STOCKS: Tata Motors Share Price Infosys Share Price IRFC Share Price SBI Card Share Price Cipla Share Price NBCC Share Price IDFC First Bank Share Price IRCTC Share Price PNB Share Price Zomato Share Price Vodafone Idea Share Price Axis Bank Share Price JSW Steel Share Price Bandhan Bank Share Price SBI Share Price Tata Steel Share Price ONGC Share Price Ashok Leyland Share Price Paytm Share Price Subex Share Price DLF Share Price Reliance Share Price HDFC Bank Share Price Suzlon Share Price IOC Share Price HUL Share Price Asian Paints Share Price Bank Of Baroda Share Price ITC Share Price TCS Share Price HFCL Share Price Icici Bank Share Price Tata Chemicals Share Price CDSI Share Price MRF Share Price Tata Power Share Price Adani Green share price BPCL Share Price Vedanta Share Price Dmart Share Price Hindalco Share Price LIC Share Price SAIL Share Price Adani Port Share Price IEX Share Price Nalco Share Price L&T Share Price Adani Power Share Price BHEL Share Price Bajaj Finance Share Price Canara Bank Share Price Indusind Bank Share Price Gail Share Price Yes Bank Share Price Wipro Share Price Happiest Minds Share Price Coal India Share Price Maruti Share Price Reliance Power Share Price

 

INDIAN INDICES: Nifty 50 Share Price SENSEX Share Price Nifty Next 50 Share Price BSE100 Share Price Nifty Bank Share Price LRGCAP Share Price Nifty 100 Share Price MIDCAP Share Price Nifty 200 Share Price SMLCAP Share Price Nifty 500 Share Price BSE500 Share Price Nifty Midcap 50 Share Price ALLCAP Share Price NIFTY SMLCAP 50 Share Price BSE200 Share Price India VIX Share Price BSEIPO Share Price

ATTENTION INVESTORS:

“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

"KYC...

loader